Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials ...

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne ...

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort.

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne ...

The 11-year-old's strength and bravery in living with the impact of the serious muscle-wasting condition was hailed by her ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent cytomegalovirus infection.

The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Wave Life Sciences Ltd. plans to file with the U.S. FDA for accelerated approval of WVE-N531, an exon skipping ...

Wave Life Sciences (WVE) stock rises on plans to file for FDA accelerated approval of WVE-N531 in 2026, targeting Duchenne muscular dystrophy. Read more here.